Enanta EDP-978 Phase 3: A $387M Micro-Cap's One-Shot Urticaria Bet

Enanta Pharmaceuticals (ENTA) closed at $13.34 with a market cap of $387 million. The company has one lead asset, EDP-978, an oral therapy for chronic urticaria with Phase 3 top-line data expected in Q4 2026. This is a classic binary biotech bet: a tiny company with one shot on goal, and the shot arrives in months.

What EDP-978 does

Chronic urticaria (hives lasting more than 6 weeks) affects roughly 1.5 million people in the U.S. The current standard of care is second-generation antihistamines, which control symptoms in about half of patients. For the rest, the options are limited. Novartis and Genentech’s Xolair (omalizumab), an injectable monoclonal antibody, is the only FDA-approved therapy for chronic spontaneous urticaria that does not respond to antihistamines. It generated $4.2 billion in 2025 revenue across all indications.

EDP-978 is an oral small molecule. Enanta has not publicly disclosed the exact mechanism in granular detail, but the drug targets the inflammatory pathway driving urticaria in a way that is distinct from antihistamines. An oral therapy that matches Xolair’s efficacy would be a meaningful commercial advance. Patients prefer pills over injections.

The Phase 3 trial

The Phase 3 program for EDP-978 is designed to measure reduction in urticaria symptom scores over 12 weeks of treatment compared to placebo. The primary endpoint is the change in the Urticaria Activity Score (UAS7), a validated patient-reported outcome that tracks hive count and itch severity over 7 days. A clinically meaningful improvement is generally considered a reduction of at least 10 points on the UAS7 scale.

The trial enrolls patients with chronic spontaneous urticaria who remain symptomatic despite standard-dose antihistamines. The comparator is placebo, with all patients on background antihistamine therapy. This is a standard design for urticaria trials and mirrors the approach used in Xolair’s registration studies.

For a framework on how to evaluate Phase 3 readouts before trading, see our guide to trading Phase 3 readouts.

What good data looks like

For EDP-978 to move the stock meaningfully, the data needs to show three things:

First, a statistically significant reduction in UAS7 versus placebo (p < 0.05). Second, a clinically meaningful effect size. Xolair achieved roughly 60% complete response rates in its Phase 3 trials. An oral competitor would need to show at least 40-50% response rates to be commercially viable. Third, a clean safety profile. Chronic urticaria is a quality-of-life condition, not a life-threatening disease. The FDA’s tolerance for safety signals is lower than it would be for oncology.

What failure looks like

If EDP-978 misses the primary endpoint, ENTA goes to cash value. Enanta had roughly $130 million in cash and equivalents as of the most recent quarter, against a $387 million market cap. That means the market is assigning roughly $257 million in value to the pipeline, almost all of it concentrated in EDP-978. A Phase 3 failure would likely cut the stock by 50-70%.

The competitive context

The urticaria market is not empty. Xolair is entrenched. Sanofi and Regeneron’s Dupixent (dupilumab) is being tested in chronic urticaria and has shown positive Phase 3 data. If Dupixent gets approved for urticaria, EDP-978 would face a second injectable competitor with strong brand recognition. An oral therapy could still differentiate on convenience, but the efficacy bar would be higher.

For context on a similar immunology readout, see our primer on ACRS’s bosakitug in atopic dermatitis.

The verdict

ENTA at $387 million is pricing in roughly a 40-50% probability of success for EDP-978, based on the gap between cash value and market cap. That is roughly in line with historical Phase 3 success rates for oral small molecules in inflammatory disease (approximately 55-60% according to BIO industry data). The stock is not cheap and not expensive. It is fairly priced for the binary risk.

The tradeable catalyst is the Q4 2026 readout. If the data is positive, ENTA doubles or triples. If it misses, the stock loses half its value. I would not hold this position without a defined risk plan. For guidance on how to structure biotech catalyst trades, see our FDA catalyst trading guide.

The specific risk: Enanta’s management has not delivered a Phase 3 success before. The company’s historical track record is in hepatitis C antivirals (part of the AbbVie regimen), not chronic inflammatory disease. A new therapeutic area is a management risk that the market may be underpricing.

Source: ClinicalTrials.gov, EDP-978 chronic urticaria